NEW YORK, NY / ACCESSWIRE / October 18, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
Textron Inc. (TXT)
Lawsuit on behalf of: investors who purchased January 31, 2018 - October 17, 2018
Lead Plaintiff Deadline : October 21, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/textron-inc-loss-form?prid=3986&wire=1
According to the filed complaint, during the class period, Textron Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) end market sales of Arctic Cat products were slowing, resulting in a massive glut of old Arctic Cat inventory on dealers' floors; (2) in order to clear out this old inventory, the Company provided significant price discounts, which negatively impacted Textron's earnings; and (3) as a result, Textron's positive statements about Arctic Cat's business, operations, and prospects lacked a reasonable basis.
MacroGenics, Inc. (MGNX)
Lawsuit on behalf of: investors who purchased February 6, 2019 - June 3, 2019
Lead Plaintiff Deadline : November 12, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/macrogenics-inc-loss-form?prid=3986&wire=1
According to the filed complaint, during the class period, MacroGenics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.
Covetrus, Inc. (CVET)
Lawsuit on behalf of: investors who purchased February 8, 2019 - August 12, 2019
Lead Plaintiff Deadline : November 29, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/covetrus-inc-loss-form?prid=3986&wire=1
According to the filed complaint, during the class period, Covetrus, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated its capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein's Animal Health Business and VFC, including the timing and nature of those costs; (iii) Covetrus had understated its separation costs from Henry Schein; and (iv) the Company understated the impact on earnings from online competition and alternative distribution channels as well as the impact of the loss of a large customer in North America just prior to the Company's separation from Henry Schein.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: